
Viz.ai Raises $50M to Expand AI-Powered Stroke ID Platform
The tech could lead to cost savings and improved patient outcomes.
Photo/Thumb have been modified. Courtesy of medistock - stock.adobe.com.
Viz.ai
Its acute ischemic stroke software uses deep-learning algorithms to identify a suspected large occlusion stroke in a CT scan and automatically notify specialists. Alerting the care provider at the right time and synchronizing care leads to quicker time to treatment and the potential for better patient outcomes.
“Viz.ai’s mission is to improve access to lifesaving treatments,” said Chris Mansi, M.D., MBA. “In stroke, by saving time for the hospital system, we can achieve significant cost savings for the payer and most importantly, improved outcomes for the patient.”
The company plans to use the funding to expand the benefits of synchronized care to other disease states and geographies.
The software is currently in use in more than 300 hospitals across the U.S.
“Viz.ai shortens time to treatment, increases the number of patients able to receive lifesaving therapy and allows us to provide the best care for our patients,” said J Mocco, M.D., professor and vice chair of the neurosurgery department at Mount Sinai Health System. “With stroke being the number one cause of long-term disability, every minute counts.”
Greenoaks led the funding, with additional participation from Threshold Ventures, CRV and existing investors GV and Kleiner Perkins.
The funding comes three months after Viz.ai and Medtronic
The clinical decision software is cleared by the U.S. Food and Drug Administration (FDA), but it is not the only technology of this kind.
Get the best insights in digital health
Related

















































